Abstract
Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung destruction. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current focus of treatment for AAT deficiency. While augmentation is a cornerstone of therapy for individuals with AAT deficiency, practitioners must also maximize standard treatment for obstructive lung disease like chronic obstructive pulmonary disease (COPD) to provide improved quality of life in patients suffering from AAT deficiency. Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics are essential therapies for the management of AAT deficiency.
Keywords: Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment. augmentation therapy, smoking cessation, pulmonary rehabilitation.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Alpha-1 Antitrypsin Deficiency: Treatment Beyond Augmentation Therapy
Volume: 9 Issue: 4
Author(s): Amit Mahajan and D. Kyle Hogarth
Affiliation:
Keywords: Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment. augmentation therapy, smoking cessation, pulmonary rehabilitation.
Abstract: Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung destruction. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current focus of treatment for AAT deficiency. While augmentation is a cornerstone of therapy for individuals with AAT deficiency, practitioners must also maximize standard treatment for obstructive lung disease like chronic obstructive pulmonary disease (COPD) to provide improved quality of life in patients suffering from AAT deficiency. Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics are essential therapies for the management of AAT deficiency.
Export Options
About this article
Cite this article as:
Mahajan Amit and Kyle Hogarth D., Alpha-1 Antitrypsin Deficiency: Treatment Beyond Augmentation Therapy, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (4) . https://dx.doi.org/10.2174/1871523011009040330
DOI https://dx.doi.org/10.2174/1871523011009040330 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Macrophage Migration Inhibitory Factor in Critical Illness
Mini-Reviews in Medicinal Chemistry Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review
Current Cardiology Reviews Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions
Current Pharmaceutical Design Cigarette Smoke-Induced Oxidant Stress in the Lung, the Unfolded Protein Response, and COPD
Current Respiratory Medicine Reviews Leukocyte-Endothelial Cell Interactions: A Therapeutic Target to Ameliorate Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism
Current Vascular Pharmacology Patent Foramen Ovale and Thromboembolic Complications
Current Pharmaceutical Design Immunologic Impact of Nutrient Depletion in Chronic Obstructive Pulmonary Disease
Current Drug Targets Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non–Small Cell Lung Cancer Models
Current Cancer Drug Targets Study of Atomic Force Microscopy in Pharmaceutical and Biopharmaceutical Interactions - A Mini Review
Current Pharmaceutical Analysis Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review
Current Cardiology Reviews Gum-Chewing and Headache: An Underestimated Trigger of Headache Pain in Migraineurs?
CNS & Neurological Disorders - Drug Targets